NewCo News: P2D Bioscience Aims Weapons At CNS, Pulmonary Disorders
By Marie Powers
Tuesday, August 2, 2011
With $9 million raised to date and nine compounds in clinical and preclinical development, P2D Bioscience Inc. already has traction in its efforts to advance product candidates for central nervous system and pulmonary disorders, including attention deficit/hyperactivity disorder (ADHD), obesity, anxiety, depression, Alzheimer's disease, traumatic brain injury and chronic obstructive pulmonary disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.